8-K: Tonix Pharmaceuticals Confirms Positive FDA Meeting for Fibromyalgia Drug Tonmya, NDA Submission on Track for Second Half of 2024

Tonix Pharmaceuticals has received positive feedback from the FDA regarding its Tonmya drug for fibromyalgia, confirming the data package is sufficient for NDA submission in the second half of 2024.

Summary

• Tonix Pharmaceuticals has completed its second and final pre-New Drug Application (NDA) meeting with the FDA for Tonmya, a potential treatment for fibromyalgia.
• The FDA has agreed that the proposed data package is sufficient to support the NDA submission for Tonmya.
• Tonix reaffirmed its plan to submit the NDA for Tonmya to the FDA in the second half of 2024.
• If approved, Tonmya could potentially be available in the second half of 2025.
• Tonmya is a centrally acting, non-opioid, non-addictive, bedtime investigational drug.
• It is a sublingual formulation of cyclobenzaprine hydrochloride.
• Fibromyalgia affects an estimated 6 to 12 million adults in the U.S., predominantly women.
• The company completed two Phase 3 trials, RELIEF and RESILIENT, which showed statistically significant pain reduction compared to placebo.
• The most common side effect was temporary tongue or mouth numbness.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful pre-NDA meeting with the FDA and the reaffirmation of the NDA submission timeline. The clinical trial results are also positive, and the focus on a non-opioid treatment is a significant advantage. However, the inherent risks of drug development temper the overall sentiment.

Positives

• The FDA has indicated that the data package for Tonmya is sufficient for NDA submission.
• The company is on track to submit the NDA in the second half of 2024.
• Tonmya has shown positive results in two Phase 3 clinical trials, demonstrating statistically significant pain reduction.
• Tonmya is a non-opioid alternative for fibromyalgia, addressing a need for non-addictive treatments.
• The most common side effect was mild and temporary.

Negatives

• The document does not explicitly mention any negatives, but it does highlight the risks associated with drug development and regulatory approval in the forward looking statements.

Risks

• The company faces risks related to obtaining FDA clearances or approvals.
• There are risks related to the successful marketing of any products.
• The timing and progress of clinical development of product candidates are uncertain.
• The company may need additional financing.
• There are uncertainties of patent protection and litigation.
• There are uncertainties of government or third party payor reimbursement.
• The company has limited research and development efforts and dependence upon third parties.
• The company faces substantial competition.

Future Outlook

Tonix plans to submit the NDA for Tonmya to the FDA in the second half of 2024, with potential FDA approval in the second half of 2025.

Management Comments

• We are delighted with the results of this critical milestone meeting with the FDA to discuss our NDA, and we are appreciative of the FDAs guidance throughout this process, said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
• We believe Tonmya has the potential to greatly benefit fibromyalgia patients, many of whom remain dissatisfied with the current treatment options, and many of whom turn to addictive, detrimental opioids as off-label treatments.

Industry Context

This announcement is significant as it represents a step forward in the development of a new treatment option for fibromyalgia, a condition with limited effective therapies. The focus on a non-opioid treatment aligns with the broader industry trend of seeking alternatives to addictive pain medications.

Comparison to Industry Standards

• The successful completion of two Phase 3 trials for Tonmya is a positive sign, as many drug candidates fail at this stage.
• The statistically significant pain reduction demonstrated by Tonmya in clinical trials is comparable to or better than some existing treatments for fibromyalgia.
• The focus on a non-opioid treatment is in line with the industry's move away from addictive pain medications, which is a significant advantage.
• Companies like Eli Lilly (with Cymbalta) and Pfizer (with Lyrica) have established treatments for fibromyalgia, but Tonmya's non-opioid nature could give it a competitive edge.
• The timeline for NDA submission and potential approval is within the typical range for pharmaceutical development.

Stakeholder Impact

• Shareholders will likely view this announcement positively as it represents progress in the development of Tonmya.
• Patients with fibromyalgia may benefit from a new, non-opioid treatment option.
• Employees of Tonix will be involved in the NDA submission process and potential commercialization of Tonmya.
• The company's suppliers and partners may see increased activity related to the production and distribution of Tonmya.

Next Steps

• Tonix will submit the NDA for Tonmya to the FDA in the second half of 2024.
• The company anticipates a potential FDA approval in the second half of 2025.

Key Dates

Keywords

Tonmya, Fibromyalgia, FDA, NDA, Clinical Trials, Pain Management, Non-opioid, Pharmaceuticals, TNXP, Drug Development